Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengqing Fentongning Sustained-Release Tablets
- Development stage
- Unknown
- Lead developer
- Zhengqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zhengqing Fentongning Sustained-Release Tablets (also known as Zhengqing Fengtongning Sustained-Release Tablets) is an approved oral traditional Chinese medicine (TCM) formulation developed by Hunan Zhengqing Pharmaceutical. The active ingredient is sinomenine hydrochloride, a morphinan alkaloid purified from the climbing plant *Sinomenium acutum*. Sinomenine hydrochloride acts as an anti-inflammatory, analgesic, and immunomodulatory agent. It exerts its therapeutic effects primarily by activating the neuronal acetylcholine receptor subunit alpha-7 (CHRNA7), the mu-type opioid receptor (OPRM1), and the aryl hydrocarbon receptor (AHR), as well as by antagonizing guanylate-binding protein 5 (GBP5). Zhengqing Fentongning Sustained-Release Tablets are approved in China for the treatment of rheumatoid arthritis and osteoarthritis, and are also being investigated for other inflammatory and neuropathic conditions, including gout, postherpetic neuralgia, diabetic kidney disease, and IgA nephropathy.
- Brand names
- Zhengqing FentongningZhengqing Fentongning Sustained-Release TabletsZhengqing FengtongningZhengqing Fengtongning Sustained-Release Tablets
- Other names
- ZFSRTZQFTNsinomenine hydrochloride sustained-release tabletssinomenine sustained-release tablets
02
Targets
MOR (Mu opioid receptor)AHR (Aryl hydrocarbon receptor)PTGES (Microsomal prostaglandin E synthase-1)CHRNA7 (α7 nicotinic receptor)GBP5 (Guanylate-binding protein 5)
Beyond the preview
Go deeper on Zhengqing Fentongning Sustained-Release Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhengqing Fentongning Sustained-Release Tablets.